Efficacy and Safety of Weekly Low Dose Paclitaxel and Cisplatin as First Line Therapy in Advanced NSCLC of Elderly Patients.
- Author:
Jung Ho LEE
1
;
Mi Hye KWON
;
Ji Hyun JEOUNG
;
Go Eun LEE
;
Eu Gene CHOI
;
Moon Jun NA
;
Hyun Min CHO
;
Young Jin KIM
;
Weon Kuu CHUNG
;
Young Jun CHO
;
Ji Woong SON
Author Information
- Publication Type:Original Article
- Keywords: Paclitaxel; Weekly; Cisplatin; Elderly; Non-small cell lung cancer
- MeSH: Aged*; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cisplatin*; Disease-Free Survival; Drug Therapy; Humans; Neutropenia; Paclitaxel*; Survival Rate
- From:Journal of Lung Cancer 2007;6(2):85-90
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE : Anti-cancer chemotherapeutic agents act by inhibiting tumor cell proliferation through cytotoxic action, therefore the generally tolerated maximum dose is administered to patients. However, this often results in the production of undesirable toxicities, such as bone marrow suppression, and a long interruption of treatment is necessary for recovery to occur before additional cycles of treatment are administered. Paclitaxel and cisplatin are well known effective chemotherapeutic agents used for the treatment of Non-Small Cell Lung Cancer (NCSLC), however, they have substantial toxicities. To evaluate efficacy and safety of a therapy consisting of a weekly low dose of paclitaxel and therapy in elderly patients with advanced NSCLC. MATERIALS AND METHODS : Thirteen treatment-naive, elderly patients over 65 years old who were diagnosed with stage IV NSCLC at Konyang University from April 2005 to October 2006 were enrolled in the present study. Paclitaxel at a dose of 55 mg/m2 in combination with cisplatin at a dose of 20 mg/m2 was administered intravenously on day 1, 8, and 15 with 1 week of interruption for a total of six cycles of chemotherapy. RESULTS : The mean age of the ten patients included in this study was 69.5 years. Following treatment, 50 % of the patients exhibited a partial response to treatment, whereas the disease remained stable in 40% of the patients, and progressed in 10% of the patients. The median survival time (Kaplan-Meier method) was 15 months (4~24 months), and the 6-month, 1-year, and 2-year survival rates were 80%, 50%, and 10%, respectively. The median progression survival time was 8 months (2~14 months) and the 6- and 12-month progression free survival rates were 60% and 10%, respectively. Grade 3 neutropenia occurred in only 1 case (10%). CONCLUSION : The results of this study indicated that chemotherapy consisting of a weekly low dose of paclitaxel and cisplatin could be more effective and have lesser toxicity when administered to elderly patients with advanced NSCLC. In addition, this treatment regimen showed a promising response rate
